The above successful trials on combinatorial therapies such as cell vaccines with IL-2, AAV co-expression of apoptin and IL-24, IL-15 and everolimus, combination therapy of intratumoral IL-12, human tyrosinase (hTyr) DNA vaccination and metronomic cyclophosphamide (CPX), heat shock protein vaccination and directed IL-2 therapy, warrant further work into the development of target-specific cancer immunotherapy treatment(s). This evidence concerns the gene IL24 and cancer.